SCHEMBL25834661

SCHEMBL25834661

NC(=O)CCC(C(=O)O)N1C(=O)c2cccc(P)c2C1=O

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.60
MEN1 O00255 1/20 0.60
ALDH1A1 P00352 3/20 0.57
POLB P06746 3/20 0.57
MAPK1 P28482 2/20 0.57
KDM4E B2RXH2 1/20 0.57
TP53 P04637 1/20 0.57
GLA P06280 1/20 0.57
CYP3A4 P08684 1/20 0.57
CYP2D6 P10635 1/20 0.57
HPGD P15428 1/20 0.57
ALOX12 P18054 1/20 0.57
NFKB1 P19838 1/20 0.57
APEX1 P27695 1/20 0.57
HSD17B10 Q99714 1/20 0.57
GAA P10253 2/20 0.46
L3MBTL1 Q9Y468 1/20 0.43
AADAT Q8N5Z0 1/20 0.39
HIF1A Q16665 1/20 0.38
DNMT1 P26358 4/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29790446 0.88 KMT2A (0.61) KMT2AMEN1ALDH1A1POLBMAPK1
SCHEMBL2168383 0.88 KMT2A (0.61) KMT2AMEN1ALDH1A1POLBMAPK1
SCHEMBL672662 0.88 KMT2A (0.61) KMT2AMEN1ALDH1A1POLBMAPK1
SCHEMBL2167853 0.87 KMT2A (0.60) KMT2AMEN1ALDH1A1POLBMAPK1
SCHEMBL23702539 0.86 KMT2A (0.58) KMT2AMEN1ALDH1A1POLBMAPK1
SCHEMBL17162091 0.86 KMT2A (0.58) KMT2AMEN1ALDH1A1POLBMAPK1
SCHEMBL5025856 0.85 KMT2A (0.57) KMT2AMEN1ALDH1A1POLBMAPK1
SCHEMBL6258804 0.85 KMT2A (0.57) KMT2AMEN1ALDH1A1POLBMAPK1
2-Phthalimidoglutaramic Acid SCHEMBL410167 0.85 ALDH1A1 (0.77) KMT2AMEN1ALDH1A1POLBMAPK1
2-Phthalimidoglutaramic Acid SCHEMBL14855879 0.85 ALDH1A1 (0.77) KMT2AMEN1ALDH1A1POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-12-14 US disclosed
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2023-07-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230219945-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KMT2A 445/4885MEN1 4055/4885ALDH1A1 2776/4885
US-20230398223-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK1 KMT2A 445/4885MEN1 4055/4885ALDH1A1 2776/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.